IR@PKUHSC  > 北京大学第一临床医学院  > 皮肤性病科
学科主题临床医学
Efficacy and Safety of 1 % Terbinafine Film-Forming Solution in Chinese Patients with Tinea Pedis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study
Li, Ruo Yu1; Wang, A. P.1; Xu, J. H.2; Xi, L. Y.3; Fu, M. H.4; Zhu, M.2; Xu, M. L.5; Li, X. Q.3; Lai, W.6; Liu, W. D.4; Lu, X. Y.5; Gong, Z. Q.6
刊名CLINICAL DRUG INVESTIGATION
2014-03-01
DOI10.1007/s40261-014-0171-8
34期:3页:223-230
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]DERMATOPHYTES
英文摘要

Superficial fungal skin infections are treated using topical antifungals. The aim of this study was to demonstrate the efficacy of a single application of 1 % terbinafine film-forming solution (FFS) versus placebo for the treatment of tinea pedis in the Chinese population.

Six centers in China randomized 290 patients in a 1:1 ratio to receive either 1 % terbinafine FFS or FFS vehicle (placebo) once on the affected foot/feet. Efficacy assessments included microscopy and mycologic culture, and assessing clinical signs and symptoms at baseline, and at weeks 1 and 6 after the topical treatment. All adverse events were recorded.

At week 6, 1 % terbinafine FFS was superior to placebo for effective treatment rate (63 vs. 8 %); clinical cure (30 vs. 6 %); mycological cure (86 vs. 12 %); negative microscopy (90 vs. 24 %); and negative mycological culture (90 vs. 27 %): all p a parts per thousand currency sign 0.001 and clinically relevant. At week 6, 1 % terbinafine FFS was clinically superior to placebo for the absence of: erythema (69 vs. 29 %); desquamation (33 vs. 8 %); and pruritus (70 vs. 30 %): all p a parts per thousand currency sign 0.001 and clinically relevant. At week 6, differences in the average total signs and symptoms scores were significantly lower for 1 % terbinafine FFS versus placebo (p a parts per thousand currency sign 0.001). Both 1 % terbinafine FFS and placebo were safe and well tolerated based on adverse events and investigator and patient assessments.

This double-blind, randomized, multicenter study demonstrated one single topical application of 1 % terbinafine FFS was safe and effective in the treatment of tinea pedis in the Chinese population.

语种英语
WOS记录号WOS:000331655400008
资助机构Beijing Novartis Pharma Ltd. ; Novartis
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/49993
专题北京大学第一临床医学院_皮肤性病科
作者单位1.Peking Univ, Hosp 1, Dept Dermatol, Beijing 100034, Peoples R China
2.Fudan Univ, Huashan Hosp, Shanghai 200433, Peoples R China
3.Sun Yat Sen Mem Hosp, Dept Dermatol, Guangzhou, Guangdong, Peoples R China
4.Chinese Acad Med Sci, Inst Dermatol, Nanjing, Jiangsu, Peoples R China
5.Peking Univ, Hosp 3, Dept Dermatol, Beijing 100034, Peoples R China
6.Sun Yat Sen Univ, Dept Dermatol, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China
推荐引用方式
GB/T 7714
Li, Ruo Yu,Wang, A. P.,Xu, J. H.,et al. Efficacy and Safety of 1 % Terbinafine Film-Forming Solution in Chinese Patients with Tinea Pedis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study[J]. CLINICAL DRUG INVESTIGATION,2014,34(3):223-230.
APA Li, Ruo Yu.,Wang, A. P..,Xu, J. H..,Xi, L. Y..,Fu, M. H..,...&Gong, Z. Q..(2014).Efficacy and Safety of 1 % Terbinafine Film-Forming Solution in Chinese Patients with Tinea Pedis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study.CLINICAL DRUG INVESTIGATION,34(3),223-230.
MLA Li, Ruo Yu,et al."Efficacy and Safety of 1 % Terbinafine Film-Forming Solution in Chinese Patients with Tinea Pedis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study".CLINICAL DRUG INVESTIGATION 34.3(2014):223-230.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Ruo Yu]的文章
[Wang, A. P.]的文章
[Xu, J. H.]的文章
百度学术
百度学术中相似的文章
[Li, Ruo Yu]的文章
[Wang, A. P.]的文章
[Xu, J. H.]的文章
必应学术
必应学术中相似的文章
[Li, Ruo Yu]的文章
[Wang, A. P.]的文章
[Xu, J. H.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。